The first quarter of 2025 saw a wave of significant advancements in clinical research across oncology, neurology, dermatology, respiratory, and rare diseases.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.